|
Opportunistic off-target cancer screening in organized programs: The EDIFICE 6 survey. |
|
|
|
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Laidet Medical; Lilly; Merck Serono; MSD; Novartis; Novartis; Roche |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Sysmex (Inst) |
|
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Laidet Medical; Pfizer; Roche; VitalAire |
Other Relationship - Inovotion |
|
|
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; GlaxoSmithKline; Intuitive Surgical; Ipsen; Janssen-Cilag; Lilly; Roche; Sanofi; Takeda |
Travel, Accommodations, Expenses - Astellas Pharma; Coloplast |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - Roche |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
Thibault De La Motte Rouge |
No Relationships to Disclose |